PL2625201T3 - Środki wiążące CD33 - Google Patents
Środki wiążące CD33Info
- Publication number
- PL2625201T3 PL2625201T3 PL11764553T PL11764553T PL2625201T3 PL 2625201 T3 PL2625201 T3 PL 2625201T3 PL 11764553 T PL11764553 T PL 11764553T PL 11764553 T PL11764553 T PL 11764553T PL 2625201 T3 PL2625201 T3 PL 2625201T3
- Authority
- PL
- Poland
- Prior art keywords
- binding agents
- binding
- agents
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP10186468 | 2010-10-04 | ||
PCT/EP2011/067339 WO2012045752A1 (en) | 2010-10-04 | 2011-10-04 | Cd33 binding agents |
EP11764553.1A EP2625201B2 (en) | 2010-10-04 | 2011-10-04 | Cd33 binding agents |
Publications (2)
Publication Number | Publication Date |
---|---|
PL2625201T3 true PL2625201T3 (pl) | 2017-05-31 |
PL2625201T5 PL2625201T5 (pl) | 2019-11-29 |
Family
ID=43296954
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PL11764553T PL2625201T5 (pl) | 2010-10-04 | 2011-10-04 | Środki wiążące CD33 |
Country Status (37)
Country | Link |
---|---|
US (4) | US9079958B2 (pl) |
EP (2) | EP3133088B1 (pl) |
JP (1) | JP5727613B2 (pl) |
KR (1) | KR101864597B1 (pl) |
CN (1) | CN103261227B (pl) |
AP (1) | AP2013006764A0 (pl) |
AR (1) | AR083293A1 (pl) |
AU (1) | AU2011311575B2 (pl) |
BR (1) | BR112013007944B1 (pl) |
CA (1) | CA2809925C (pl) |
CL (1) | CL2013000669A1 (pl) |
CO (1) | CO6710907A2 (pl) |
CY (1) | CY1119691T1 (pl) |
DK (1) | DK2625201T4 (pl) |
EA (1) | EA026360B1 (pl) |
EC (1) | ECSP13012597A (pl) |
ES (1) | ES2605014T5 (pl) |
GE (1) | GEP20166429B (pl) |
HK (1) | HK1184165A1 (pl) |
HR (1) | HRP20161656T4 (pl) |
HU (1) | HUE030150T2 (pl) |
IL (1) | IL224984A (pl) |
LT (1) | LT2625201T (pl) |
MA (1) | MA34546B1 (pl) |
MX (1) | MX344522B (pl) |
MY (1) | MY160485A (pl) |
NZ (1) | NZ607969A (pl) |
PE (1) | PE20140194A1 (pl) |
PL (1) | PL2625201T5 (pl) |
PT (1) | PT2625201T (pl) |
RS (1) | RS55317B2 (pl) |
SG (1) | SG189023A1 (pl) |
SI (1) | SI2625201T2 (pl) |
TW (1) | TWI535734B (pl) |
UA (1) | UA112062C2 (pl) |
UY (1) | UY33647A (pl) |
WO (1) | WO2012045752A1 (pl) |
Families Citing this family (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
UA112062C2 (uk) | 2010-10-04 | 2016-07-25 | Бьорінгер Інгельхайм Інтернаціональ Гмбх | Cd33-зв'язувальний агент |
EA201700111A1 (ru) | 2011-10-28 | 2018-02-28 | Тева Фармасьютикал Австралия Пти Лтд | Полипептидные конструкции и их применение |
WO2013173820A2 (en) | 2012-05-18 | 2013-11-21 | Scott & White Healthcare | Bispecific scfv immunofusion (bif) |
US20130309223A1 (en) * | 2012-05-18 | 2013-11-21 | Seattle Genetics, Inc. | CD33 Antibodies And Use Of Same To Treat Cancer |
CN104936977B (zh) * | 2012-10-24 | 2019-10-08 | 开普敦大学 | 微管修饰化合物 |
SG10201913777XA (en) * | 2013-03-13 | 2020-03-30 | Sanofi Sa | Compositions comprising anti-cd38 antibodies and carfilzomib |
RS59925B1 (sr) | 2013-07-05 | 2020-03-31 | H Lee Moffitt Cancer Center And Research Institute Inc | Rastvorljivi cd33 za lečenje mijelodisplastičnih sindroma (mds) |
AR097648A1 (es) | 2013-09-13 | 2016-04-06 | Amgen Inc | Combinación de factores epigenéticos y compuestos biespecíficos que tienen como diana cd33 y cd3 en el tratamiento de leucemia mieloide |
WO2015067570A2 (en) * | 2013-11-06 | 2015-05-14 | Boehringer Ingelheim International Gmbh | Pharmaceutical combinations comprising cd33 antibodies and de-methylating agents |
MA39095A1 (fr) * | 2013-12-13 | 2018-08-31 | Genentech Inc | Anticorps et immunoconjugués anti-cd33 |
US9212225B1 (en) | 2014-07-01 | 2015-12-15 | Amphivena Therapeutics, Inc. | Bispecific CD33 and CD3 binding proteins |
EP3302555A4 (en) | 2015-05-29 | 2018-07-11 | Amphivena Therapeutics, Inc. | Methods of using bispecific cd33 and cd3 binding proteins |
WO2016201389A2 (en) | 2015-06-12 | 2016-12-15 | Alector Llc | Anti-cd33 antibodies and methods of use thereof |
US11136390B2 (en) | 2015-06-12 | 2021-10-05 | Alector Llc | Anti-CD33 antibodies and methods of use thereof |
CN115960235A (zh) | 2015-08-28 | 2023-04-14 | 艾利妥 | 抗siglec-7抗体及其使用方法 |
WO2017160954A1 (en) | 2016-03-15 | 2017-09-21 | Seattle Genetics, Inc. | Combinations of pbd-based antibody drug conjugates with bcl-2 inhibitors |
EP3463463A4 (en) | 2016-06-03 | 2020-01-15 | Seattle Genetics, Inc. | COMBINATION OF CD33 ANTIBODY-ACTIVE SUBSTANCE CONJUGATES WITH CHEMOTHERAPEUTICS |
WO2017214433A1 (en) | 2016-06-09 | 2017-12-14 | Seattle Genetics, Inc. | Combinations of pbd-based antibody drug conjugates with flt3 inhibitors |
WO2018057802A1 (en) | 2016-09-21 | 2018-03-29 | Aptevo Research And Development Llc | Cd123 binding proteins and related compositions and methods |
MY191926A (en) | 2016-12-01 | 2022-07-18 | Regeneron Pharma | Radiolabeled anti-pd-l1 antibodies for immuno-pet imaging |
CN106834300B (zh) * | 2017-03-06 | 2019-12-31 | 李斯文 | 一种抗cd33单链抗体及光敏剂复合物及其制备方法 |
JP7305613B2 (ja) * | 2017-07-09 | 2023-07-10 | バイオサイト リミテッド | 併用がん療法 |
WO2019028292A1 (en) | 2017-08-03 | 2019-02-07 | Alector Llc | ANTI-TREM2 ANTIBODIES AND METHODS OF USE |
KR20200033798A (ko) | 2017-08-03 | 2020-03-30 | 알렉터 엘엘씨 | 항-cd33 항체 및 이의 이용 방법 |
CA3087346A1 (en) * | 2018-01-08 | 2019-07-11 | Actinum Pharmaceuticals, Inc. | Combination immunotherapy and chemotherapy for the treatment of a hematological malignancy |
EP3740507A4 (en) | 2018-01-15 | 2022-08-24 | Nanjing Legend Biotech Co., Ltd. | SINGLE DOMAIN ANTIBODIES AND VARIANTS THEREOF AGAINST PD-1 |
EP3749346A4 (en) | 2018-02-08 | 2021-12-15 | Dragonfly Therapeutics, Inc. | VARIABLE DOMAINS OF ANTIBODIES TARGETING THE NKG2D RECEIVER |
MX2020008683A (es) * | 2018-02-20 | 2020-12-07 | Dragonfly Therapeutics Inc | Dominios variables de anticuerpo que se dirigen a cd33 y sus usos. |
GB201806084D0 (en) * | 2018-04-13 | 2018-05-30 | Berlin Chemie Ag | Antibodies |
JOP20190116A1 (ar) | 2018-05-24 | 2019-11-24 | Janssen Biotech Inc | الأجسام المضادة لتكتل التمايز 33 (cd33)، والأجسام المضادة ثنائية النوعية لتكتل التمايز 33 (cd33)/تكتل التمايز 3 (cd3) واستخداماتها |
CN112512638A (zh) | 2018-06-08 | 2021-03-16 | 艾利妥 | 抗siglec-7抗体及其使用方法 |
EA202190235A1 (ru) | 2018-08-31 | 2021-07-02 | Алектор Ллс | Антитела к cd33 и способы их применения |
EP3850011A4 (en) * | 2018-09-10 | 2022-10-19 | Nanjing Legend Biotech Co., Ltd. | SINGLE DOMAIN ANTIBODIES AGAINST CD33 AND USES THEREOF |
CN112672757A (zh) * | 2018-09-25 | 2021-04-16 | 中央研究院 | 抗-唾液酸结合性免疫球蛋白样凝集素的抗体、包括该抗体的药学组合物及其用途 |
MX2023003041A (es) | 2020-09-16 | 2023-05-09 | Amgen Inc | Métodos para administrar dosis terapéuticas de moléculas de acoplamiento a células t biespecíficas para el tratamiento de cáncer. |
WO2023081898A1 (en) | 2021-11-08 | 2023-05-11 | Alector Llc | Soluble cd33 as a biomarker for anti-cd33 efficacy |
WO2023114510A2 (en) | 2021-12-17 | 2023-06-22 | Denali Therapeutics Inc. | Polypeptide engineering, libraries, and engineered cd98 heavy chain and transferrin receptor binding polypeptides |
Family Cites Families (71)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2036891B (en) | 1978-12-05 | 1983-05-05 | Windsor Smith C | Change speed gear |
GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
NO169637C (no) | 1983-10-11 | 1992-07-22 | Fidia Spa | Fremgangsmaate for fremstilling av terapeutisk aktive hyaluronsyre-fraksjoner |
JPS6147500A (ja) | 1984-08-15 | 1986-03-07 | Res Dev Corp Of Japan | キメラモノクロ−ナル抗体及びその製造法 |
EP0173494A3 (en) | 1984-08-27 | 1987-11-25 | The Board Of Trustees Of The Leland Stanford Junior University | Chimeric receptors by dna splicing and expression |
GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
JPS61134325A (ja) | 1984-12-04 | 1986-06-21 | Teijin Ltd | ハイブリツド抗体遺伝子の発現方法 |
JP2532858B2 (ja) | 1985-04-01 | 1996-09-11 | セルテツク リミテツド | 形質転換したミエロ―マ細胞系 |
WO1987002671A1 (en) | 1985-11-01 | 1987-05-07 | International Genetic Engineering, Inc. | Modular assembly of antibody genes, antibodies prepared thereby and use |
GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
WO1988007089A1 (en) | 1987-03-18 | 1988-09-22 | Medical Research Council | Altered antibodies |
GB8717430D0 (en) | 1987-07-23 | 1987-08-26 | Celltech Ltd | Recombinant dna product |
US5047335A (en) | 1988-12-21 | 1991-09-10 | The Regents Of The University Of Calif. | Process for controlling intracellular glycosylation of proteins |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
EP1690935A3 (en) | 1990-01-12 | 2008-07-30 | Abgenix, Inc. | Generation of xenogeneic antibodies |
US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
KR100272077B1 (ko) | 1990-08-29 | 2000-11-15 | 젠팜인터내셔날,인코포레이티드 | 이종 항체를 생산할 수 있는 전이유전자를 가진 인간이외의 동물 |
US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5278299A (en) | 1991-03-18 | 1994-01-11 | Scripps Clinic And Research Foundation | Method and composition for synthesizing sialylated glycosyl compounds |
EP1260521B1 (en) | 1991-08-14 | 2007-11-21 | Genentech Inc. | Immunoglobulin variants for specific Fc epsilon receptors |
AU3144193A (en) | 1991-11-21 | 1993-06-15 | Board Of Trustees Of The Leland Stanford Junior University | Controlling degradation of glycoprotein oligosaccharides by extracellular glycosisases |
ZA932523B (en) * | 1992-04-10 | 1994-10-08 | Res Dev Foundation | Immunotoxins directed against cd33 related surface antigens |
US5773001A (en) † | 1994-06-03 | 1998-06-30 | American Cyanamid Company | Conjugates of methyltrithio antitumor agents and intermediates for their synthesis |
US5739277A (en) | 1995-04-14 | 1998-04-14 | Genentech Inc. | Altered polypeptides with increased half-life |
CA2249195A1 (en) | 1996-03-18 | 1997-09-25 | Board Of Regents, The University Of Texas System | Immunoglobin-like domains with increased half lives |
US5834597A (en) | 1996-05-20 | 1998-11-10 | Protein Design Labs, Inc. | Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same |
AU3968897A (en) | 1996-08-02 | 1998-02-25 | Bristol-Myers Squibb Company | A method for inhibiting immunoglobulin-induced toxicity resulting from the use of immunoglobulins in therapy and in vivo diagnosis |
US5888809A (en) | 1997-05-01 | 1999-03-30 | Icos Corporation | Hamster EF-1α transcriptional regulatory DNA |
ATE472599T1 (de) | 1997-11-21 | 2010-07-15 | Human Genome Sciences Inc | Chemokin alpha-5 |
CA2320403A1 (en) | 1998-02-25 | 1999-09-02 | Lexigen Pharmaceuticals Corporation | Enhancing the circulating half-life of antibody-based fusion proteins |
CA2323757C (en) | 1998-04-02 | 2011-08-02 | Genentech, Inc. | Antibody variants and fragments thereof |
GB9809951D0 (en) | 1998-05-08 | 1998-07-08 | Univ Cambridge Tech | Binding molecules |
EP3569610A3 (en) | 2000-12-12 | 2020-03-18 | Medlmmune, LLC | Molecules with extended half lives, compositions and uses thereof |
US20030133939A1 (en) | 2001-01-17 | 2003-07-17 | Genecraft, Inc. | Binding domain-immunoglobulin fusion proteins |
US20040002587A1 (en) | 2002-02-20 | 2004-01-01 | Watkins Jeffry D. | Fc region variants |
US20040132101A1 (en) | 2002-09-27 | 2004-07-08 | Xencor | Optimized Fc variants and methods for their generation |
US20040110226A1 (en) | 2002-03-01 | 2004-06-10 | Xencor | Antibody optimization |
US7317091B2 (en) | 2002-03-01 | 2008-01-08 | Xencor, Inc. | Optimized Fc variants |
JP4459810B2 (ja) | 2002-08-14 | 2010-04-28 | マクロジェニクス,インコーポレーテッド | FcγRIIB特異的抗体とその利用法 |
ES2562177T3 (es) | 2002-09-27 | 2016-03-02 | Xencor Inc. | Variantes de Fc optimizadas y métodos para su generación |
ATE480562T1 (de) | 2002-10-15 | 2010-09-15 | Facet Biotech Corp | Veränderung von fcrn-bindungsaffinitäten oder von serumhalbwertszeiten von antikörpern mittels mutagenese |
WO2004043344A2 (en) * | 2002-11-07 | 2004-05-27 | Immunogen, Inc. | Anti-cd33 antibodies and method for treatment of acute myeloid leukemia using the same |
US7960512B2 (en) | 2003-01-09 | 2011-06-14 | Macrogenics, Inc. | Identification and engineering of antibodies with variant Fc regions and methods of using same |
JP2006524039A (ja) | 2003-01-09 | 2006-10-26 | マクロジェニクス,インコーポレーテッド | 変異型Fc領域を含む抗体の同定および作製ならびにその利用法 |
US20060003412A1 (en) | 2003-12-08 | 2006-01-05 | Xencor, Inc. | Protein engineering with analogous contact environments |
EP1697520A2 (en) | 2003-12-22 | 2006-09-06 | Xencor, Inc. | Fc polypeptides with novel fc ligand binding sites |
WO2005092925A2 (en) | 2004-03-24 | 2005-10-06 | Xencor, Inc. | Immunoglobulin variants outside the fc region |
WO2006019447A1 (en) | 2004-07-15 | 2006-02-23 | Xencor, Inc. | Optimized fc variants |
WO2006031994A2 (en) | 2004-09-14 | 2006-03-23 | Xencor, Inc. | Monomeric immunoglobulin fc domains |
WO2006047350A2 (en) | 2004-10-21 | 2006-05-04 | Xencor, Inc. | IgG IMMUNOGLOBULIN VARIANTS WITH OPTIMIZED EFFECTOR FUNCTION |
KR101019525B1 (ko) | 2004-11-12 | 2011-03-07 | 젠코어 인코포레이티드 | FcRn에 대한 변경된 결합성을 갖는 Fc 변이체 |
TW200726776A (en) * | 2005-07-29 | 2007-07-16 | Friedrich Alexander University Of Erlangen Nuremberg | CD33-specific single-chain immunotoxin and methods of use |
DK1931709T3 (en) | 2005-10-03 | 2017-03-13 | Xencor Inc | FC VARIETIES WITH OPTIMIZED FC RECEPTOR BINDING PROPERTIES |
WO2008058021A2 (en) | 2006-11-02 | 2008-05-15 | Seattle Genetics, Inc. | Methods of treating neoplastic, autoimmune and inflammatory diseases |
CN101210048A (zh) * | 2006-12-29 | 2008-07-02 | 中国医学科学院血液学研究所 | 用于靶向结合髓系白血病细胞的抗cd33的工程抗体及其表达载体和用途 |
AU2008234020B2 (en) | 2007-04-03 | 2013-02-07 | Amgen Research (Munich) Gmbh | Cross-species-specific CD3-epsilon binding domain |
ES2432792T5 (es) | 2007-04-03 | 2023-01-16 | Amgen Res Munich Gmbh | Dominio de unión a CD3-épsilon específico de especies cruzadas |
PE20140196A1 (es) | 2007-08-09 | 2014-03-19 | Boehringer Ingelheim Int | Anticuerpos anti-cd37 |
WO2010037838A2 (en) | 2008-10-01 | 2010-04-08 | Micromet Ag | Cross-species-specific single domain bispecific single chain antibody |
KR101820535B1 (ko) | 2008-10-01 | 2018-01-19 | 암젠 리서치 (뮌헨) 게엠베하 | 종간특이적 psmaxcd3 이중특이적 단일쇄 항체 |
MX338038B (es) | 2008-10-01 | 2016-03-30 | Amgen Res Munich Gmbh | Anticuerpo de una sola cadena bis-especifico de pscaxcd3, cd19xcd3, c-metxcd3, endosialinaxcd3, epcamxcd3, igf-1rxcd3 o fapalfaxcd3 de especies cruzadas. |
AR080795A1 (es) | 2010-03-24 | 2012-05-09 | Genentech Inc | Anticuerpos anti-lrp6 (proteina relacionada con el receptor ldl tipo 6) |
MX2012012927A (es) | 2010-05-06 | 2013-05-01 | Novartis Ag | Composiciones y metodos de uso para anticuerpos multivalentes terapeuticos de proteina relacionada con lipoproteina de baja densidad 6 (lrp6). |
UA112062C2 (uk) | 2010-10-04 | 2016-07-25 | Бьорінгер Інгельхайм Інтернаціональ Гмбх | Cd33-зв'язувальний агент |
WO2014029752A1 (en) | 2012-08-22 | 2014-02-27 | Glaxo Group Limited | Anti lrp6 antibodies |
-
2011
- 2011-04-10 UA UAA201305316A patent/UA112062C2/uk unknown
- 2011-09-27 US US13/246,022 patent/US9079958B2/en active Active
- 2011-10-03 AR ARP110103669 patent/AR083293A1/es active IP Right Grant
- 2011-10-03 TW TW100135799A patent/TWI535734B/zh active
- 2011-10-03 UY UY33647A patent/UY33647A/es not_active Application Discontinuation
- 2011-10-04 EP EP16185559.8A patent/EP3133088B1/en active Active
- 2011-10-04 LT LTEP11764553.1T patent/LT2625201T/lt unknown
- 2011-10-04 AU AU2011311575A patent/AU2011311575B2/en active Active
- 2011-10-04 PT PT117645531T patent/PT2625201T/pt unknown
- 2011-10-04 GE GEAP201113079A patent/GEP20166429B/en unknown
- 2011-10-04 CN CN201180058450.0A patent/CN103261227B/zh active Active
- 2011-10-04 AP AP2013006764A patent/AP2013006764A0/xx unknown
- 2011-10-04 JP JP2013529681A patent/JP5727613B2/ja active Active
- 2011-10-04 WO PCT/EP2011/067339 patent/WO2012045752A1/en active Application Filing
- 2011-10-04 PE PE2013000782A patent/PE20140194A1/es active IP Right Grant
- 2011-10-04 EA EA201300419A patent/EA026360B1/ru not_active IP Right Cessation
- 2011-10-04 MA MA35771A patent/MA34546B1/fr unknown
- 2011-10-04 MY MYPI2013001005A patent/MY160485A/en unknown
- 2011-10-04 RS RS20161031A patent/RS55317B2/sr unknown
- 2011-10-04 HU HUE11764553A patent/HUE030150T2/en unknown
- 2011-10-04 SG SG2013020326A patent/SG189023A1/en unknown
- 2011-10-04 PL PL11764553T patent/PL2625201T5/pl unknown
- 2011-10-04 ES ES11764553T patent/ES2605014T5/es active Active
- 2011-10-04 EP EP11764553.1A patent/EP2625201B2/en active Active
- 2011-10-04 SI SI201131030T patent/SI2625201T2/sl unknown
- 2011-10-04 NZ NZ607969A patent/NZ607969A/en unknown
- 2011-10-04 DK DK11764553.1T patent/DK2625201T4/da active
- 2011-10-04 BR BR112013007944-4A patent/BR112013007944B1/pt active IP Right Grant
- 2011-10-04 MX MX2013003743A patent/MX344522B/es active IP Right Grant
- 2011-10-04 CA CA2809925A patent/CA2809925C/en active Active
- 2011-10-04 KR KR1020137010652A patent/KR101864597B1/ko active IP Right Grant
-
2013
- 2013-02-28 IL IL224984A patent/IL224984A/en active IP Right Grant
- 2013-03-11 CL CL2013000669A patent/CL2013000669A1/es unknown
- 2013-04-08 CO CO13090540A patent/CO6710907A2/es unknown
- 2013-04-30 EC ECSP13012597 patent/ECSP13012597A/es unknown
- 2013-10-10 HK HK13111407.9A patent/HK1184165A1/zh not_active IP Right Cessation
-
2015
- 2015-06-18 US US14/742,836 patent/US9550833B2/en active Active
-
2016
- 2016-11-24 CY CY20161101217T patent/CY1119691T1/el unknown
- 2016-12-05 HR HRP20161656T patent/HRP20161656T4/hr unknown
- 2016-12-12 US US15/375,313 patent/US10202451B2/en active Active
-
2018
- 2018-12-17 US US16/221,811 patent/US20190256593A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20161656T1 (hr) | Sredstva za vezanje na cd33 | |
AP3107A (en) | 5-Alkynyl-pyrimidines | |
EP2547244A4 (en) | PRESS-FRUIT COMBINED WITH A MIXER | |
GB201015324D0 (en) | Secure association | |
EP2381186A4 (en) | COIL SUPPORT ELEMENT | |
EP2572199A4 (en) | COMBINATION | |
EP2571358A4 (en) | COMBINATION | |
GB201001546D0 (en) | Knocktop | |
SG10201508549UA (en) | Modified tamavidin | |
GB201116856D0 (en) | Schraubspindellagerung | |
EP2603078A4 (en) | COMBINATION | |
EP2575460A4 (en) | COMBINATION | |
GB201004001D0 (en) | Sachet | |
TWM400980U (en) | Binding | |
GB201013489D0 (en) | Binding surfaces | |
TWM389093U (en) | Binding device | |
GB201005275D0 (en) | Agents to prevent binding | |
AU4536P (en) | TB01 Tibouchina urvilleana | |
AU4937P (en) | FlatinsulGL Myoporum insulare | |
AU4932P (en) | FlatwaxpinkGL Chamelaucium uncinatum | |
AU4931P (en) | FlatwaxDarkGL Chamelaucium uncinatum | |
AU4822P (en) | FlatwaxwhiteGL Chamelaucium uncinatum | |
GB201019374D0 (en) | Pet-waste kit | |
GB201001038D0 (en) | Trailer | |
EP2654755A4 (en) | COMBINATION |